Compare
Cannabis Bioscience International Holdings, Inc. vs OneMedNet Corp vs iSpecimen Inc. vs MaxCyte, Inc.
| Latest fiscal year | Cannabis Bioscience International Holdings, Inc. CBIH | OneMedNet Corp ONMD | iSpecimen Inc. ISPC | MaxCyte, Inc. MXCT |
|---|---|---|---|---|
| Year ended | 2025-05-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $303.0K | $1.36M | $1.93M | $33.03M |
| Revenue growth (YoY) | +21.8% | +111.4% | -79.2% | -14.5% |
| Gross margin | 86.8% | -37.0% | 1.2% (computed) | 81.2% |
| Operating margin | -139.1% | -711.3% | -465.4% | -157.1% |
| Net margin | -181.1% | -206.1% | -543.7% | -135.1% |
| Net income | -$548.8K | -$2.80M | -$10.49M | -$44.63M |
| EPS (Diluted) | $0.00 | -$0.06 | -$2.28 | -$0.42 |
| Operating cash flow | -$329.6K | -$7.50M | -$4.24M | -$34.41M |
| Free cash flow | n/a | -$7.52M | -$4.24M | -$36.18M |
| Cash & equivalents | n/a | $585.0K | $6.88M | $20.07M |
| Total assets | $31.9K | $2.15M | $9.53M | $202.51M |
| Total liabilities | $1.20M | $5.12M | $6.44M | $31.02M |
| Shareholders' equity | -$1.16M | -$2.96M | $3.09M | $171.49M |
| Return on year-end equity | n/a | n/a | -339.6% | -26.0% |
| Shares outstanding | 11.63B | 51.98M | 8.48M | 106.79M |
Revenue, most recent five fiscal years
| Fiscal year | Cannabis Bioscience International Holdings, Inc. | OneMedNet Corp | iSpecimen Inc. | MaxCyte, Inc. |
|---|---|---|---|---|
| Latest | $303.0K Ended 2025-05-31 | $1.36M Ended 2025-12-31 | $1.93M Ended 2025-12-31 | $33.03M Ended 2025-12-31 |
| 1 year earlier | $248.8K Ended 2024-05-31 | $643.0K Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $38.63M Ended 2024-12-31 |
| 2 years earlier | $316.8K Ended 2023-05-31 | $1.02M Ended 2023-12-31 | $9.93M Ended 2023-12-31 | $41.29M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.15M Ended 2022-12-31 | $10.40M Ended 2022-12-31 | $44.26M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $11.14M Ended 2021-12-31 | $33.89M Ended 2021-12-31 |